U S PHYSICAL THERAPY INC /NV (USPH): Entry into a Material Definitive Agreement

U S PHYSICAL THERAPY INC /NV (USPH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ITEM 1.01 Entry into a Material Definitive Agreement. On September 22, 2026, U.S. Physical Therapy, Inc.(the "Company") entered into a 45-month forward-starting interest rate swap agreement (the “Swap”) with Bank of America, National Association (“Bank of America”) with an initia

Event · Debt financing
Instrument
forward-starting interest rate swap agreement
Amount
$170.6 million
Interest rate
4.578%
Maturity
April 14, 2031

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 28, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$USPH
Neutral
high confidence
Mentioned
$USPH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$USPHNeutralLow
01

Why it matters

The swap reduces exposure to rising rates, which could improve cash‑flow stability and support the stock.

02

Market read

A primary disclosure of a sizable interest‑rate hedge for a small‑cap healthcare firm.

03

What to watch

Potential covenant implications under the Credit Agreement and the credit rating impact.

Relevance 6/10Novelty 7/10Timing: post‑market filing

Background

US Physical Therapy Inc. disclosed a material definitive agreement to hedge interest rate risk on its term loan.

Company-level read

Ticker impact

$USPHNeutralHigh confidence
Context

USPH filed an 8‑K reporting a $170.6 million forward‑starting interest‑rate swap fixing its debt at 4.578% through 2031.

Expected impact

potential modest upside as the market prices in lower fixed‑rate cost versus variable SOFR exposure

Evidence & confidence

Fixed‑rate at 4.578% is below projected SOFR levels, likely viewed positively by investors.

Market effects

May influence other healthcare providers' financing strategies as rates rise.

Limited to USPH and its debt holders; no broad regional effect.

Minimal global impact; primarily a company‑specific financing disclosure.

Counterpoint

If SOFR falls sharply, the fixed rate could become a drag on earnings.

Key entities

  • U S Physical Therapy Inc.

    Issuer of the swap and subject of the 8‑K filing.

  • Bank of America, N.A.

    Administrative agent and swap counterparty.

Related articles

$USPHMedAI 8/10

U.S. Physical Therapy Q3 Earnings Call Highlights

U.S. Physical Therapy (USPH) reported Q3 earnings, with adjusted physical therapy margins rising 60 basis points YoY to 19%, despite higher medical costs. The company plans acquisitions and clinic expansions. Industrial injury prevention revenue grew 14% to $33M. GAAP net income fell to $11M from $13M YoY. USPH ended Q3 with $38M in cash and $247M in borrowings.

$USPHHigh

USPH Reports Third Quarter 2026 Results

U S PHYSICAL THERAPY INC /NV (USPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. CONTACT: U.S. Physical Therapy, Inc. Nchacha Etta, Chief Financial Officer email: netta@usph.com (713) 297-7000 Three Part Advisors Joe Noyons (817) 778-8424 USPH Reports Third Quarter 2026 Results, Record High Visits and Revenue Per Visit Houston, TX, November 4, 2026 – U.S. Phy

$USPHHigh

US Physical Therapy Inc (USPH) (Q3 2026) Earnings Call Highlights: Record Visits

US Physical Therapy Inc (USPH) reported Q3 2026 revenue growth of 13% to $223M, driven by record patient visits and hospital affiliations. Net rate per visit hit $112, and EBITDA grew over 16%. The company reaffirmed full-year EBITDA guidance of $102M-$106M but faced higher self-insured group health costs and increased interest expenses. Management expects continued growth from hospital partnerships and cautious about medical cost trends.